BioRealm has been selected by NVIDIA to be part of their Inception Program, designed to nurture "dedicated and exceptional startups who are revolutionizing industries with advances in AI and data science."
NVIDIA marketed the world's first Graphical Processing Unit (GPU) in 1999, and today are the world's largest manufacturer and developer of GPUs. NVIDIA GPUs have become an essential tool for those working in virtual reality, high performance computing, and artificial intelligence.
We are extremely honored to have been selected by NVIDIA and to receive such recognition by an industry giant that has played an extraordinary role in the renaissance of artificial intelligence.
NVIDIA's generous support will allow us to provide even more value to our clients, and we are excited to see what we can all create together.
In this interview with Carolyn Ervin, biostatistician, and co-founder of BioRealm, we discuss how to get the most value from experienced biostatisticians, developments in the industry and her associated concerns, a few of her favorite tools when working on clinical trials, and project management secrets.
Estimated reading time: 4 minutes, 51 seconds
In this interview with James Baurley, data scientist, and co-founder of BioRealm, LLC., we discuss how biological markers, especially genetic biological markers, may be used in clinical trials, and a few of the computational and statistical issues and limitations.
Estimated reading time: 4 minutes, 43 seconds
If you recently took advantage of the United States' National Institute on Drug Abuse's (NIDA) program offering free genotyping on our Smokescreen® genotyping array to substance abuse disorder investigators, remember to also take advantage of our full suite of services for clinical trials using biological markers (biomarkers). You can also learn more about Smokescreen in BMC Genomics.
Designed specifically for researchers interested in the causes of addiction and its treatment.
More addiction-related content than any other commercially available array
Covers 98% of common genetic variation in 1000+ addiction genes
More than 296K markers, selected for African, East Asian, and European populations
More than 20K markers from expert nomination, knowledge-bases, candidate gene arrays, and the literature
More nicotine and tobacco related content than any other commercially available array
- More than 11K markers in the nicotine acetylcholine receptor gene cluster3 and nicotine metabolizer regions4
- More than 16K markers for related co-morbidities and diseases
Better genome-wide imputation coverage of common variants than most similarly-sized arrays
- African (66%), East Asian (82%), and European (91%)
1 Developed with support from the United States National Institute on Drug Abuse (NIDA).
2 For research use only. Not for use in diagnostic procedures.
BioRealm was founded in 2006 by Drs James W. Baurley and Carolyn M. Ervin while both were researchers at the University of Southern California, Los Angeles, California. Our team and our scientific advisors have made fundamental contributions to scientific research and have published extensively.
Our diverse team of experts includes biostatisticians, clinical geneticists, computational geneticists, entrepreneurs, genetic epidemiologists, statistical geneticists, machine learning researchers, computational biologists, and software engineers from all over the world. We believe that the convergence of advances in both genomics and artificial intelligence will fundamentally transform the future, and we are excited to work at the leading edge of that wave as we help our clients.
WE ARE BIOREALM
James W. Baurley, PhD
James earned his doctorate in statistical genetics and genetic epidemiology from the University of Southern California, Los Angeles, California, and both his master's in biostatistics and bachelor's in computer science from Clemson University, Clemson, South Carolina.
Carolyn M. Ervin, PhD
Carolyn earned her doctorate in epidemiology from the University of Southern California, Los Angeles, California; her master's in public health from The University of California, Los Angeles, California; and both her master's in applied mathematics and bachelor's in mathematics from Western Michigan University, Kalamazoo, Michigan.
Andrew W. Bergen, PhD
Andrew earned his doctorate in genetics from George Washington University, Washington, D.C., United States; his master's in genetics from Johns Hopkins University, Baltimore, Maryland; and a bachelor's in biology from Haverford College, Haverford, Pennsylvania.
Carissa I. PardameaN, MSc
Carissa is a doctoral candidate in medical and molecular pharmacology at the University of California, Los Angeles, California. She earned her master's in biomedical sciences from Boston University, Boston, Massachusetts, and her double bachelor’s degree in linguistics and molecular and cell biology with an emphasis in genetics from the University of California, Berkeley, California. She is also a computational geneticist for Bina Nusantara University, Jakarta, Indonesia.
Conor SEÁN Ryan
Conor started developing software at fifteen, joined American Mensa at seventeen, and become a professional mainframe software developer and systems administrator at eighteen. He has over thirty years of software engineering, database engineering, and systems administration experience, including seventeen years in medical research with institutions such as the University of Southern California, Los Angeles, California.
He studied at Excelsior College, formerly Regent's College, Albany, New York.
SCIENTIFIC AND STRATEGIC ADVISORS
David V. Conti, PhD
David is Professor in the Division of Biostatistics, the Zilkha Neurogenetic Institute, and the Norris Cancer Center at the University of Southern California, Los Angeles, California. He was trained in genetic epidemiology and biostatistics at Case Western Reserve University and was awarded the 2001 Roger Williams award from the International Genetic Epidemiology Society (IGES). He has also been a Visiting Fellow at Churchill College, University of Cambridge.
Chris S. McMahan, PhD
Chris earned his doctorate in statistics from the University of South Carolina, Columbia, South Carolina; his master's in mathematics from Western Kentucky University, Bowling Green, Kentucky; and his bachelor's in mathematics from Austin Peay State University, Clarksville, Tennessee.
He is currently an Assistant Professor in the Department of Mathematical Sciences at Clemson University, Clemson, South Carolina.
Doug Levinson, JD, MBA
Doug earned his doctorate from the University of Southern California, Los Angeles, California, his master's in business administration from the University of California, Los Angeles, California, and bachelor's degrees in English literature and biological psychology, having studied at the University of California, Berkeley, California; the University of Oxford, Oxford, England; and Stanford University, Stanford, California.
StephEn McGee, MS
Stephen is a doctoral candidate in biomedical data science at Clemson University, Clemson, South Carolina. He earned his master's in bioinformatics from the University of North Carolina, Charlotte, North Carolina, and his bachelor's in experimental psychology from the University of South Carolina, Columbia, South Carolina. He is a Bioinformatics Specialist with the Molecular Diagnostic Laboratory at the Greenwood Genetic Center, Greenwood, South Carolina, and is also a Research Assistant in Clemson University's Computer Science Department.
Bens Pardamean, PhD
Bens earned his doctorate in informative research from the University of Southern California, Los Angeles, California, and both his master’s in computer education and bachelor’s degree in computer science from California State University, Los Angeles, California.
He is the Director of Bina Nusantara University's Bioinformatics and Data Science Research Center and an Associate Professor of Computer Science at the Bina Nusantara University, Jakarta, Indonesia.
"Because of the SmokeScreen® array, we have the ability to reveal genetic information previously hidden in NIDA's samples. We have great confidence in SmokeScreen® ‒ it is a validated platform that will become a crucial tool in advancing addiction research and moving the field towards personalized treatment."
— Dr. Andrew Brooks, RUCDR Infinite Biologics’ Chief Operating Officer and Director of Technology Development
“We are excited to be part of BioRealm’s vision of improving human health by providing insight into the genetics of tobacco-related illness. It was a pleasure to work with BioRealm’s team of dedicated scientists to co-develop this cutting-edge technology.”
— Dr. Frank R. Witney, President and Chief Executive Officer of Affymetrix